1. Multitarget Effect of 2-(4-(Methylthio)phenyl)-3-(3-(piperidin-1-yl)propyl)thiazolidin-4-one in a Scopolamine-Induced Amnesic Rat Model.
- Author
-
da Silva DS, Soares MSP, Teixeira FC, de Mello JE, de Souza AA, Luduvico KP, de Andrade CM, Spanevello RM, and Cunico W
- Subjects
- Acetylcholinesterase metabolism, Animals, Avoidance Learning drug effects, Cerebral Cortex drug effects, Cerebral Cortex enzymology, Hippocampus drug effects, Hippocampus enzymology, Male, Memory Disorders chemically induced, Memory Disorders enzymology, Oxidative Stress drug effects, Rats, Wistar, Scopolamine, Sodium-Potassium-Exchanging ATPase metabolism, Rats, Memory Disorders prevention & control, Nootropic Agents therapeutic use, Piperidines therapeutic use, Thiazolidines therapeutic use
- Abstract
Cholinergic system dysfunction, oxidative damage, and alterations in ion pump activity have been associated with memory loss and cognitive deficits in Alzheimer's disease. 1,3-thiazolidin-4-ones have emerged as a class of compounds with potential therapeutic effects due to their potent anticholinesterase activity. Accordingly, this study investigated the effect of the 2-(4-(methylthio)phenyl)-3-(3-(piperidin-1-yl)propyl)thiazolidin-4-one (DS12) compound on memory, cholinergic and oxidative stress parameters, ion pump activity, and serum biochemical markers in a scopolamine-induced memory deficit model. Male Wistar rats were divided into four groups: I-Control; II-Scopolamine; III-DS12 (5 mg/kg) + scopolamine; and IV-DS12 (10 mg/kg) + scopolamine. The animals from groups III and IV received DS12 diluted in canola oil and administered for 7 days by gavage. On the last day of treatment, scopolamine (1 mg/kg) was administered intraperitoneally (i.p.) 30 min after training in an inhibitory avoidance apparatus. Twenty-four hours after scopolamine administration, the animals were subjected to an inhibitory avoidance test and were thereafter euthanized. Scopolamine induced memory deficits, increased acetylcholinesterase activity and oxidative damage, and decreased Na
+ /K+ -ATPase activity in cerebral cortex and hippocampus. Pretreatment with DS12 prevented these brain alterations. Scopolamine also induced an increase in acetylcholinesterase activity in lymphocytes and whereas butyrylcholinesterase in serum and treatment with DS12 prevented these changes. In animals treated with DS12, no changes were observed in renal and hepatic parameters when compared to the control group. In conclusion, DS12 emerged as an important multitarget compound capable of preventing neurochemical changes associated with memory deficits.- Published
- 2021
- Full Text
- View/download PDF